RxDoctor Payments DataLook up a doctor →

Arelis Madera, MD

Endocrinology, Diabetes & Metabolism · Port Charlotte, FLNPI 1487697272

Payments from drug & device makers

$1,673,351in general payments, 2019–2025

Across 3,131 payments — averaging $534.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$633K
  • Novo Nordisk$374K
  • Bayer$229K
  • Dexcom, Inc.$148K
  • Abbott$74K
  • AstraZeneca$56K
  • plus $160K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC1,072$632,544
Novo Nordisk422$374,109
Bayer249$229,334
Dexcom, Inc.161$148,062
Abbott133$73,658
AstraZeneca104$56,031
Sanofi-aventis U.S. LLC129$50,060
Xeris Pharmaceuticals, Inc.90$28,112
AbbVie(2 entities)64$18,371
Amgen(2 entities)81$15,642
Radius Health, Inc.70$13,546
Johnson & Johnson53$6,946
Senseonics, Incorporated19$6,081
Merck10$4,041
Neurocrine Biosciences, Inc.14$3,918
Ascensia Diabetes Care US Inc.5$2,704
Insulet Corporation83$1,339
Zealand Pharma US, Inc.15$1,085
Mannkind Corporation59$862
Tandem Diabetes Care, Inc.31$680
Novartis28$497
Corcept Therapeutics19$455
Medtronic(2 entities)25$450
Astellas Pharma US Inc9$384
Chiesi USA, Inc.1$325
Ascendis Pharma Endocrinology Inc9$318
BETA Bionics, Inc.14$300
Almatica Pharma LLC18$284
Valeritas, Inc.10$266
Recordati_rare_diseases_inc.7$248
Lifescan, Inc.15$212
Amarin Pharma, Inc.12$209
Vanda Pharmaceuticals Inc.7$178
Companion Medical, Inc.10$158
Amneal Pharmaceuticals LLC7$135
IBSA Pharma Inc.8$135
Madrigal Pharmaceuticals5$129
Takeda Pharmaceuticals U.S.A., Inc.1$125
Paratek Pharmaceuticals, Inc.1$125
Kyowa Kirin, Inc.3$117
Averitas Pharma Inc.5$112
Nevro Corp.6$112
Cequr Corporation3$111
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$89
Regeneron Healthcare Solutions, Inc.5$86
Boehringer Ingelheim4$77
Nestle Healthcare Nutrition Inc.5$67
Currax Pharmaceuticals LLC3$55
GRT US Holding, Inc.2$55
Esperion Therapeutics, Inc.2$47
Ultragenyx Pharmaceutical Inc.2$46
Shire North American Group Inc2$43
Aimmune Therapeutics, Inc.3$40
Sequel Med Tech, LLC2$40
Ipsen Biopharmaceuticals, Inc2$40
Pfizer2$35
Rhythm Pharmaceuticals, Inc.1$33
Kowa Pharmaceuticals America, Inc.2$30
Lexicon Pharmaceuticals, Inc.1$21
Vivus LLC1$20

How this compares

$1,673,351 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$393,911
Medicare patients
1,056
Services billed
6,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Port Charlotte

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →